Skip directly to Accessibility Notice

PPH
VanEck Pharmaceutical ETF

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

 
 

  • Fund Ticker

    PPH
  • Exchange

    NASDAQ
  • Inception Date

    12/20/2011
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Index Ticker

    MVPPHTR
  • Index Rebalancing

    Quarterly

  as of 12/06/22

  • 30-Day SEC Yield1

    1.75%
  • Total Net Assets

    $590.6M
  • Number of Holdings

    25
  • Options

    Available
  • Gross Expense Ratio2

    0.35%
  • Net Expense Ratio/TER2

    0.35%
  • Distribution Frequency

    Quarterly
  • Next Distribution Date

    12/27/2022

Fund Highlights

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

  • Industry Leaders
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    PPH
  • Index Total Return Ticker

    MVPPHTR
  • NAV

    PPHNV
  • Intraday NAV (IIV)4

    PPHIV
  • Shares Outstanding

    7,588,138
  • Estimated Cash

    PPHEU
  • Total Cash

    PPHTC
  • CUSIP

    92189F692
  • ISIN

    US92189F6925
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%
  • Other Expenses

    --
  • Acquired Fund Fees and Expenses

    --
  • Gross Expense Ratio

    0.35%
  • Fee Waivers and
    Expense Reimbursement

    --
  • Net Expense Ratio/TER2

    0.35%

2Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.

Morningstar™ Ratings3 as of 10/31/2022

Category Overall 3 Year 5 Year
Health

Morningstar Ratings: When applicable, ratings shown when the ETF is rated three stars or more for any given period. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics.

© Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Investment Professionals

  • Portfolio Manager and Head of Equity ETFs
  • Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
  • Joined VanEck in 2005
  • CFA charterholder; member of the CFA Society New York
  • BA, Mathematics and Economics, New York University
  • Analyst for Equity ETFs
  • Joined VanEck in 2018
  • Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
  • BS, Finance, Providence College
  • Analyst for Equity ETFs
  • Joined VanEck in 2019
  • Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
  • BS, Accounting, Hunter College

Prices as of 12/06/22

NAV/
Market
Price
Volume
30-Day Avg./
Last Trading Day
Daily Change
NAV/
Last Price
YTD Change NAV/
Last Price
Premium/
Discount
30-Day
Median
Bid Ask
Spread
NAV
Chart
PPH $77.83
$77.87
142,733
200,732
$0.27 / +0.35%
$0.23 / +0.30%
+2.41%
+2.45%
$0.04
0.05%
0.03%

Premium/Discount History as of 12/06/22

Calendar Year 2021 4Q 2021 1Q 2022 2Q 2022 3Q 2022 Premium/Discount Charts NAV & Prem/Discount History
PPH Days closed at a premium 146 41 29 30 26
Days closed at NAV 24 8 9 7 3
Days closed at a discount 82 15 24 25 35

Performance History: Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) 5.85 9.49 1.49 9.69 9.29 7.98 8.93 9.39
PPH (Share Price) 5.74 9.32 1.35 9.58 9.25 7.93 8.93 9.48
MVPPHTR (Index) 5.82 9.46 1.38 9.49 9.00 7.78 8.82 9.28
Performance Differential (NAV - Index) 0.03 0.03 0.11 0.20 0.29 0.20 0.11 0.11
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
PPH (NAV) -4.93 -12.20 -11.86 -5.91 7.55 4.92 7.35 8.12
PPH (Share Price) -4.95 -12.21 -11.88 -6.10 7.51 4.92 7.36 8.22
MVPPHTR (Index) -4.91 -12.24 -11.93 -6.07 7.27 4.73 7.25 8.01
Performance Differential (NAV - Index) -0.02 0.04 0.07 0.16 0.28 0.19 0.10 0.11

Top 10 Holdings (%) as of 11/30/22

Daily Holdings
Total Holdings: 25
Holding Name
Ticker
Shares
Market Value
(US$)
% of Net
Assets
Johnson & Johnson
JNJ US
291,610
51,906,580 8.81
Eli Lilly & Co
LLY US
93,224
34,593,562 5.87
Merck & Co Inc
MRK US
311,430
34,294,672 5.82
Abbvie Inc
ABBV US
211,188
34,039,282 5.78
Novo Nordisk A/S
NVO US
258,079
32,156,643 5.46
Pfizer Inc
PFE US
630,463
31,605,110 5.36
Bristol-Myers Squibb Co
BMY US
393,458
31,586,808 5.36
Astrazeneca Plc
AZN US
452,262
30,740,248 5.22
Novartis Ag
NVS US
334,253
29,935,699 5.08
Haleon Plc
HLN US
4,162,189
28,677,482 4.87
Top 10 Total (%) 57.63
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%)
as of 11/30/22

Country % of Net Assets
United States 62.77
United Kingdom 14.62
Denmark 5.46
Switzerland 5.08
France 4.63
Japan 4.57
Israel 2.84
Other/Cash 0.02

Sector Weightings (%)
as of 11/30/22

Sector % of Net Assets
Health Care 95.11
Consumer Staples 4.87
Other/Cash 0.02

View More Funds

loading...